Home

Tal Zvi Zaks

CIK 1690927 · Chief Medical Officer · last filed 2026-08-10

Tal Zvi Zaks is a Chief Medical Officer who has filed 92 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing shows the insider sold $593 of TEVA on Aug 10, 2026. Across all open-market trades the lifetime net is −$124.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.4M across reported positions. 13 SEC filings were submitted jointly with TEVA PHARMACEUTICAL INDUSTRIES LTD.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.44M

Companies

4

Total Filings

92

Lifetime Open-Market Net

-$124.16M

Filer Profile

Reported Address
C/O ADAPTIMMUNE THERAPEUTICS PLC
60 JUBILEE AVE, MILTON PARK
ABINGDON, OXFORDSHIRE, X0 OX14 4RX
Related Filers
TEVA PHARMACEUTICAL INDUSTRIES LTD — 13 joint filings, latest 2026-08-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TEVA Director 73,247 $37.09 $2.72M -$593 11 2026-08-10
Adaptimmune Therapeutics PLC (ADAP) Delisted Director — $0.06 — $0 3 2022-07-01
MRNA Chief Medical Officer 5,000 $143.97 $719.9K -$124.16M 74 2021-07-02
ASND Director — $263.51 — $0 4 2019-07-03

Recent Filings

92 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-10 TEVA Sell (S) −17 -$593 EDGAR
2026-06-08 TEVA Exer (M) +14,492 $0 EDGAR
2026-06-01 TEVA Grant (A) — $0 EDGAR
2025-06-09 TEVA Mixed +9,632 $0 EDGAR
2024-06-17 TEVA Exer (M) +21,108 $0 EDGAR
2024-06-10 TEVA Grant (A) — $0 EDGAR
2023-08-07 TEVA Exer (M) +15,810 $0 EDGAR
2023-06-20 TEVA Grant (A) — $0 EDGAR
2022-11-07 TEVA Exer (M) +12,205 $0 EDGAR
2022-08-08 TEVA Grant (A) — $0 EDGAR
Showing 1–10 of 92
Page 1 of 10
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.